Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

Extended Survival and Prognostic Factors for Patients WithALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis

(2016) Kimberly L. Johung et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

(2015) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

(2015) Giulio Metro et al.   Journal of Thoracic Oncology

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

(2015) Justin F. Gainor et al.   Journal of Thoracic Oncology

Future options for ALK-positive non-small cell lung cancer

(2015) Daniela Iacono et al.   LUNG CANCER

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

(2014) Tatsushi Kodama et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

(2011) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER